Elsevier

European Urology Supplements

Volume 11, Issue 1, February 2012, Pages e130, e130a
European Urology Supplements

130 Overall survival benefit and impact on skeletal-related events for radium-223 chloride (Alpharadin) in the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases: A phase III randomized trial (ALSYMPCA)

https://doi.org/10.1016/S1569-9056(12)60129-8Get rights and content

References (0)

Cited by (0)

View full text